BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 19021908)

  • 1. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda.
    Abaasa AM; Todd J; Ekoru K; Kalyango JN; Levin J; Odeke E; Karamagi CA
    BMC Health Serv Res; 2008 Nov; 8():241. PubMed ID: 19021908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Survival analysis of HIV/AIDS patients with access to highly antiretroviral therapy in Ningbo during 2004-2015].
    Zhang JH; Li HL; Shi HB; Jiang HB; Hong H; Dong HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Sep; 37(9):1262-1267. PubMed ID: 27655575
    [No Abstract]   [Full Text] [Related]  

  • 4. Frequency and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda.
    Rubaihayo J; Tumwesigye NM; Konde-Lule J; Wamani H; Nakku-Joloba E; Makumbi F
    BMC Res Notes; 2016 Dec; 9(1):501. PubMed ID: 27927247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with long-term antiretroviral therapy attrition among adolescents in rural Uganda: a retrospective study.
    Okoboi S; Ssali L; Yansaneh AI; Bakanda C; Birungi J; Nantume S; Okullu JL; Sharp AR; Moore DM; Kalibala S
    J Int AIDS Soc; 2016; 19(5 Suppl 4):20841. PubMed ID: 27443271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for Kaposi's sarcoma in human immunodeficiency virus patients after initiation of antiretroviral therapy: A nested case-control study in Kenya.
    Lupia R; Wabuyia PB; Otiato P; Fang CT; Tsai FJ
    J Microbiol Immunol Infect; 2017 Dec; 50(6):781-788. PubMed ID: 26712092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality and progression to AIDS after starting highly active antiretroviral therapy.
    van Sighem AI; van de Wiel MA; Ghani AC; Jambroes M; Reiss P; Gyssens IC; Brinkman K; Lange JM; de Wolf F;
    AIDS; 2003 Oct; 17(15):2227-36. PubMed ID: 14523280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda.
    Weidle PJ; Wamai N; Solberg P; Liechty C; Sendagala S; Were W; Mermin J; Buchacz K; Behumbiize P; Ransom RL; Bunnell R
    Lancet; 2006 Nov; 368(9547):1587-94. PubMed ID: 17084759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sex specific mortality in HIV/AIDS patients receiving antiretroviral therapy and risk factors in Xinjiang Uygur autonomous region].
    Ni M; Chen X; Ma Y; Hu X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2015 Sep; 36(9):971-5. PubMed ID: 26814865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
    Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
    Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
    BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes.
    Chung MH; Richardson BA; Tapia K; Benki-Nugent S; Kiarie JN; Simoni JM; Overbaugh J; Attwa M; John-Stewart GC
    PLoS Med; 2011 Mar; 8(3):e1000422. PubMed ID: 21390262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of progression to AIDS after HIV infection diagnosis in the pre- and post-HAART eras in a Brazilian AIDS-free cohort.
    Tancredi MV; Waldman EA
    Trans R Soc Trop Med Hyg; 2014 Jul; 108(7):408-14. PubMed ID: 24836061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of AIDS patients in Sao Paulo-Brazil in the pre- and post-HAART eras: a cohort study.
    Tancredi MV; Waldman EA
    BMC Infect Dis; 2014 Nov; 14():599. PubMed ID: 25398533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART).
    Kim JH; Psevdos G; Gonzalez E; Singh S; Kilayko MC; Sharp V
    Infection; 2013 Apr; 41(2):545-51. PubMed ID: 23264096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.